A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

November 30, 2025

Conditions

Type2 Diabetes Mellitus

Interventions

DRUG

Comparator 1

Dapagliflozin 10mg + Linagliptin 5mg

DRUG

Comparator 2

Metformin 1000mg

DRUG

Test Drug

Fixed-dose combination tablet (AJU-A53)

Trial Locations (1)

Chung-Ang University Gwangmyeong Hospital, Gwangmyeong

All Listed Sponsors

lead

AJU Pharm Co., Ltd.

INDUSTRY